For Admin

  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2012〜
  • CONTACT

Shin Nippon Biomedical Laboratories, Ltd. Translational Research Business

Japanese

A Leading Company in Nasal Drug Delivery

  • HOME
  • BUSINESS
  • TECHNOLOGY
    • Platform Technology
    • Special Analysis
    • Publication
  • APPLICATION
    • Absorption
    • Vaccination
    • Nose-to-Brain
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY

Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Widely Applicable Technology

For Absorption
For Vaccination
For Nose-to-Brain

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next

News

2024

Nov 26, 2024

SNBL’s Subsidiary, Satsuma Pharmaceuticals Receives FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

Oct 31, 2024

SNBL’s Subsidiary Satsuma Pharmaceuticals Resubmits New Drug Application for STS101 for Acute Treatment of Migraine With or Without Aura

Jan 18, 2024

FDA Issues Complete Response Letter for Satsuma’s STS101

2025|2024|2023|2022|2021|2020〜

BACK
  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY
Cookie Policy | Sitemap
© Shin Nippon Biomedical Laboratories, Ltd. All Rights Reserved.
Log out | Edit